Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Techtimes

Published November 16, 2026 · Updated November 17, 2026

Psychedelic Add-On for Depression Beats Placebo by 7.6 Points in Phase 3, Blinding Data Missing

Read the full story at Techtimes

Psychedelic depression treatment HLP003 beat placebo by 7.6 MADRS points at Week 6 in Helus Pharma's first Phase 3 trial of an adjunctive.

Surfaced by this Google Alert

  • Psychedelics